Study finds no significant benefit of spironolactone in HFpEF or HFmrEF

A trial testing the aldosterone blocker spironolactone in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) did not show any significant improvement in terms of heart failure hospitalizations and cardiovascular death at 24 months, according to findings presented at the American College of Cardiology's Annual Scientific Session (ACC.26).